Anti-Infectives and Antimicrobials Review and Outlook 2011

Anti-infective products include antibacterials, antifungals, antivirals, and vaccines. The global market value for anti-infectives is one pace to top $100 billion within the next few years. Growth is expected to be lead by the launch of novel medicines for drug-resistant bacteria, a rise in the rate of severe fungal infections, and the availability of new antiviral and HIV drugs.

Additional Information

This special report focuses on the market leaders for anti-infectives and antimicrobials as well as the products in development anticipated to head this area in the years to come. This compilation’s prescription-product pipeline details the following information for each medicine: chemical or substance composition, intended indication, class of drug, clinical status, region of development, and the product developer/intended marketer. Pipeline status details preclinical development, Phase I, Phase I/II, Phase II, Phase II/III, Phase III, and awaiting approval. Regions of development include the United States, Europe, and Japan. A directory of anti-infectives and antimicrobials prescription-drug developers and marketers is included.

Additionally provided in this report is a listing of anti-infectives and antimicrobials medical-device entries, sorted by device class, as well as a directory of medical-device companies associated with the anti-infectives and antimicrobials field.